Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70


The cost and challenge of vaccine development for emerging and emergent infectious diseases.

Maslow JN.

Lancet Glob Health. 2018 Oct 17. pii: S2214-109X(18)30418-2. doi: 10.1016/S2214-109X(18)30418-2. [Epub ahead of print] No abstract available.


Assay Challenges for Emerging Infectious Diseases: The Zika Experience.

Roberts CC, Maslow JN.

Vaccines (Basel). 2018 Oct 2;6(4). pii: E70. doi: 10.3390/vaccines6040070. Review.


Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization.

de La Vega MA, Piret J, Griffin BD, Rhéaume C, Venable MC, Carbonneau J, Couture C, das Neves Almeida R, Tremblay RR, Magalhães KG, Park YK, Roberts CC, Maslow JN, Sardesai NY, Kim JJ, Muthumani K, Weiner DB, Kobinger GP, Boivin G.

J Infect Dis. 2018 Jul 24. doi: 10.1093/infdis/jiy336. [Epub ahead of print]


Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus.

Kudchodkar SB, Choi H, Reuschel EL, Esquivel R, Jin-Ah Kwon J, Jeong M, Maslow JN, Reed CC, White S, Kim JJ, Kobinger GP, Tebas P, Weiner DB, Muthumani K.

Microbes Infect. 2018 Mar 17. pii: S1286-4579(18)30070-4. doi: 10.1016/j.micinf.2018.03.001. [Epub ahead of print]


In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.

Muthumani K, Griffin BD, Agarwal S, Kudchodkar SB, Reuschel EL, Choi H, Kraynyak KA, Duperret EK, Keaton AA, Chung C, Kim YK, Booth SA, Racine T, Yan J, Morrow MP, Jiang J, Lee B, Ramos S, Broderick KE, Reed CC, Khan AS, Humeau L, Ugen KE, Park YK, Maslow JN, Sardesai NY, Joseph Kim J, Kobinger GP, Weiner DB.

NPJ Vaccines. 2016 Nov 10;1:16021. doi: 10.1038/npjvaccines.2016.21. eCollection 2016.


Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report.

Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, Boyer J, Park YK, Trottier S, Remigio C, Krieger D, Spruill SE, Bagarazzi M, Kobinger GP, Weiner DB, Maslow JN.

N Engl J Med. 2017 Oct 4. doi: 10.1056/NEJMoa1708120. [Epub ahead of print]


Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.

Maslow JN.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2918-2930. doi: 10.1080/21645515.2017.1358325. Epub 2017 Aug 28. Review.


DNA vaccination protects mice against Zika virus-induced damage to the testes.

Griffin BD, Muthumani K, Warner BM, Majer A, Hagan M, Audet J, Stein DR, Ranadheera C, Racine T, De La Vega MA, Piret J, Kucas S, Tran KN, Frost KL, De Graff C, Soule G, Scharikow L, Scott J, McTavish G, Smid V, Park YK, Maslow JN, Sardesai NY, Kim JJ, Yao XJ, Bello A, Lindsay R, Boivin G, Booth SA, Kobasa D, Embury-Hyatt C, Safronetz D, Weiner DB, Kobinger GP.

Nat Commun. 2017 Jun 7;8:15743. doi: 10.1038/ncomms15743.


Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection.

Lee H, Jeong M, Oh J, Cho Y, Shen X, Stone J, Yan J, Rothkopf Z, Khan AS, Cho BM, Park YK, Weiner DB, Son WC, Maslow JN.

Sci Rep. 2017 Mar 7;7:43531. doi: 10.1038/srep43531.


Vaccine development for emerging virulent infectious diseases.

Maslow JN.

Vaccine. 2017 Oct 4;35(41):5437-5443. doi: 10.1016/j.vaccine.2017.02.015. Epub 2017 Feb 16.


Impact of microbiology cascade reporting on antibiotic de-escalation in cefazolin-susceptible Gram-negative bacteremia.

Johnson LS, Patel D, King EA, Maslow JN.

Eur J Clin Microbiol Infect Dis. 2016 Jul;35(7):1151-7. doi: 10.1007/s10096-016-2645-5. Epub 2016 Apr 29.


Tuberculosis in elephants-a reemergent disease: diagnostic dilemmas, the natural history of infection, and new immunological tools.

Maslow JN, Mikota SK.

Vet Pathol. 2015 May;52(3):437-40. doi: 10.1177/0300985814568357. Epub 2015 Jan 29.


The international threat of antimicrobial resistance: the perils of paradise.

Maslow JN.

Infect Control Hosp Epidemiol. 2013 Feb;34(2):125-6. doi: 10.1086/669079. Epub 2012 Dec 19. No abstract available.


Mycobacterium avium serovars 2 and 8 infections elicit unique activation of the host macrophage immune responses.

Cebula BR, Rocco JM, Maslow JN, Irani VR.

Eur J Clin Microbiol Infect Dis. 2012 Dec;31(12):3407-12. doi: 10.1007/s10096-012-1709-4. Epub 2012 Sep 19.


Genitourinary and pulmonary multidrug resistant Mycobacterium tuberculosis infection in an Asian elephant (Elephas maximus).

Dumonceaux GA, St Leger J, Olsen JH, Burton MS, Ashkin D, Maslow JN.

J Zoo Wildl Med. 2011 Dec;42(4):709-12.


Global distribution and epidemiologic associations of Escherichia coli clonal group A, 1998-2007.

Johnson JR, Menard ME, Lauderdale TL, Kosmidis C, Gordon D, Collignon P, Maslow JN, Andrasević AT, Kuskowski MA; Trans-Global Initiative for Antimicrobial Resistance Analysis Investigators.

Emerg Infect Dis. 2011 Nov;17(11):2001-9. doi: 10.3201/eid1711.110488.


Tuberculosis at the human-animal interface: an emerging disease of elephants.

Mikota SK, Maslow JN.

Tuberculosis (Edinb). 2011 May;91(3):208-11. doi: 10.1016/ Epub 2011 Mar 11. Review.


Risk factors for fecal colonization with multiple distinct strains of Escherichia coli among long-term care facility residents.

Lautenbach E, Tolomeo P, Black N, Maslow JN.

Infect Control Hosp Epidemiol. 2009 May;30(5):491-3. doi: 10.1086/597234.


Impact of diversity of colonizing strains on strategies for sampling Escherichia coli from fecal specimens.

Lautenbach E, Bilker WB, Tolomeo P, Maslow JN.

J Clin Microbiol. 2008 Sep;46(9):3094-6. doi: 10.1128/JCM.00945-08. Epub 2008 Jul 23.


Bacterial characteristics as predictors of posttherapy recurrent bacteriuria among children with acute uncomplicated cystitis caused by Escherichia coli.

Johnson JR, Johnston B, Murray A, Kuskowski MA, Maslow JN, Johnson C.

Pediatr Infect Dis J. 2007 Dec;26(12):1151-3.


Supplemental Content

Loading ...
Support Center